Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate Dupilumab Schedule in Recurrent CRSwNP
NCT06750471Phase 4Active, not recruiting
- Sponsor
- Madigan Army Medical Center
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Madigan Army Medical Center. Primary endpoints: Sinonasal Outcome Test-22 at 28 weeks, Lund Kennedy Score at 28 weeks and 2 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06750471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750471.